Avadel Pharmaceuticals
Preço: 21.64Empresa e modelo de negócios
Avadel Pharmaceuticals is a healthcare company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Its core products include the sodium oxybate formulation, which targets narcolepsy, and other specialty pharmaceuticals. The company primarily generates revenue through product sales and licensing agreements.
Perfil de investimento
The investment profile of Avadel Pharmaceuticals is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income, as it does not currently offer dividends.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 0.00 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- 13.7% ↑
- Surpresa de EPS
- -162.5% pior que o esperado
- Volatilidade 20d
- 0.2% estável
Dados FMP / FinFeed atualizados:
2026-06-13
Rec.: Manter
Potencial: 56
Risco: 70
Atualizado: 2026-06-13 02:50
Como a recomendação funciona
Por que a IA pensa assim:
Weak fundamentals and high risk limit upside potential.
Acompanhar no portfólio
Gráfico de preço
Recomendação da IA
Previsão do analista
Evento de calendário
Sinal positivo
Sinal negativo
Neutro / atualização
Manter / informativo
B My buy
S My sell
Mudanças na recomendação da IA
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-05-08 15:06 | — | Manter | Weak fundamentals and high risk offset potential upside. |
| 2026-05-08 05:19 | Manter | Manter | Компания показывает положительную динамику роста за последние 60 и 120 дней, однако низкий EPS и отрицательный сюрприз по доходам указывают на определенные риски. |
| 2026-03-27 07:56 | Comprar | Manter | Компания показывает рост за последние 60 и 120 дней, однако низкий EPS и высокая степень неожиданности в отчетах указывают на потенциальные риски. |
Previsões de analistas
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2025-11-20 11:38 | Wells Fargo | Preço-alvo elevado | 20 → 22.5 | 23.015 |
| 2025-10-28 07:48 | UBS | Atualizar | — → 20 | 18.56 |
| 2025-10-23 11:37 | H.C. Wainwright | Rating rebaixado | — → 20 | 18.525 |
Nada ainda